Samples reactive by first-generation recombinant immunoblot assay (RIBA) to detect antibody to hepatitis C virus (anti-HCV) Calif.]) remained reactive by a second-generation test (RIBA-2) for HCV antibodies. A total of 75% of specimens indeterminate by RIBA-1 became reactive, 12.5% were nonreactive, and 12.5% remained-indeterminate by RIBA-2. Among RIBA-1-nonreactive specimens, 12.0% became positive and 5.1% became indeterminate by RIBA-2. The antigens c33c and c22-3 have increased the sensitivity of RIBA-2.
Samples reactive by first-generation recombinant immunoblot assay (RIBA) to detect antibody to hepatitis C virus (anti-HCV) (RIBA-1 [Chiron, Calif.]) remained reactive by a second-generation test (RIBA-2) for HCV antibodies. A total of 75% of specimens indeterminate by RIBA-1 became reactive, 12.5% were nonreactive, and 12.5% remained-indeterminate by RIBA-2. Among RIBA-1-nonreactive specimens, 12.0% became positive and 5.1% became indeterminate by RIBA-2. The antigens c33c and c22-3 have increased the sensitivity of RIBA-2.
A recombinant immunoblot assay (RIBA), the RIBA HCV (RIBA-1; Chiron Corporation, Calif.), distributed by Ortho Diagnostics Systems (Raritan, N.J.), has been used for confirming samples positive for hepatitis C virus (HCV) antibody (anti-HCV) (2, 3) by enzyme immunoassay (6) . RIBA-1 contains immobilized bands of two recombinant HCV antigens (clOO-3, produced in yeast, and 5-1-1, produced in Escherichia coli) and superoxide dismutase on nitrocellulose strips. Superoxide dismutase is included because it is part of the recombinant expression vector. Recently, a second-generation RIBA HCV (RIBA-2) has been developed, in which two additional recombinant antigens (c33c [NS3 region] and c22-3 [virus core]) have been added. Both antigens were expressed in yeast.
RIBA-1 identifies samples as reactive, indeterminate, or nonreactive. The indeterminate test result creates a problem for immediate diagnosis of hepatitis C.
RIBA-2 was reported to be more sensitive and specific than the first-generation test (8) and was said to be more useful in differentiating infective and noninfective blood donors (8) . The problem of indeterminate test results appears to be still unsolved, but the extent of indeterminate results by RIBA-2 has not been reported.
In this study, we compared the performance of RIBA-2 on samples selected on the basis of their reactivity by RIBA-1 for anti-HCV.
Three groups of samples were selected on the basis of RIBA-1 results. They consisted of 25 reactive, 56 indeterminate, and 58 nonreactive samples. These samples were from different risk groups although this was not the basis for selection.
Of the samples tested, 25 were from hemodialysis patients, 13 were from prisoners, 14 were from hemophiliacs, 3 were from blood product users, 3 were from health care workers, and 81 were from patients without known risk factors. Anti-HCV-positive (enzyme immunoassay [Ortho Diagnostics]) samples were tested by RIBA-1, and then representative numbers of samples from reactive, indeterminate, and nonreactive groups were tested by the RIBA-2 kit.
The tests were performed and interpreted according to the recommended protocols. A reaction to both clOO-3 and 5-1-1 antigens was considered positive, whereas no reaction to * Corresponding author. either of these two bands was considered negative. Reaction to any one of the antigen bands was considered indeterminate. Reactivity to the superoxide dismutase band alone was considered negative, but reactivity to the superoxide dismutase and to clOO-3 and/or 5-1-1 was considered indeterminate. For RIBA-2, sera reacting with two or more of the four RIBA antigens (5-1-1, clOO-3, c33c, and c22-3) were considered positive for anti-HCV, those reacting with only one antigen were considered indeterminate, and those with no reaction to any of the antigen bands were considered negative. The degree of antibody reactivity was assessed by comparison with a weak and strong immunoglobulin G positive control.
The results (Table 1) showed that all 25 samples testing positive for anti-HCV by RIBA-1 were also reactive by RIBA-2. However, 42 of 56 (75%) of the samples defined as indeterminate by RIBA-1 were positive by RIBA-2, and 12.5% were nonreactive. Thus, RIBA-2 provides a clear diagnosis for 87.5% of the RIBA-1-indeterminate samples.
Only a small number of samples (12.5%) remained indeterminate following RIBA-2.
Among the samples that were nonreactive by RIBA-1, 12.0% were positive by RIBA-2, and 5.1% were indeterminate. However, most of the samples (82.7%) remained nonreactive by both tests. These results showed that there is some improvement in the sensitivity of second-generation RIBA HCV.
The pattern of antigen reactivity for RIBA-2 is shown in Table 2 . Results showed that all RIBA-1-reactive samples remained positive by RIBA-2 but the pattern of antigen reactivity changed. Twelve samples reactive to antigens 5-1-1 and clOO-3 by RIBA-1 were also reactive to c33c and c22-3 by RIBA-2. However, five samples lost reactivity (1+) to 5-1-1 and clOO-3 when tested by RIBA-2, and six lost their reactivity to clOO-3 alone. This showed that weak antigen reactivity (1+) could change in subsequent testing by RIBA-2.
Thirty-three RIBA-1-indeterminate samples became positive by RIBA-2, as demonstrated by their reactivity to c33c and c22-3 antigens. Seven samples were positive by RIBA-2, as demonstrated by their reactivity to c22-3 in combination with 5-1-1 or clOO-3. Two samples were positive, as demonstrated by their reactivity to 5-1-1 and c33c. Seven RIBA-1-indeterminate samples became nonreactive by RIBA-2, as four samples lost reactivity to 5-1-1 and three lost reactivity to clOO-3.
Seven RIBA-1 nonreactive samples became positive by RIBA-2, as six reacted to c33c and c22-3 antigens while one reacted to 5-1-1 and c33c.
The distribution of patients with respect to risk factors and test results is given in Table 3 . Results showed that most (64.2%) of the RIBA-1 indeterminate samples which proved reactive by RIBA-2 were drawn from the high-risk groups. However, 35.7% of the samples from individuals without any known risk factors were also positive by RIBA-2. A further breakdown of the data from RIBA-1-indeterminate samples showed that samples from 62.5% of the hemodialysis patients, 81.8% of the prisoners, 100% of the hemophiliacs, and 100% of the blood product users were reactive by RIBA-2 but not by RIBA-1. Among health care workers, only 33.3% of the samples became reactive by RIBA-2. These groups are known (1, 4, 5, 7) to have a high prevalence of anti-HCV. Some of the RIBA-1-nonreactive samples were reactive by RIB3A-2. These samples were from prisoners, hemophiliacs, and blood product users. Among samples from the unknown group, 9.1% were reactive by RIBA-2 but not by RIBA-1.
In conclusion, it appears that RIBA-2 is more sensitive than RIBA-1 for the detection of anti-HCV. Furthermore, the analysis of antigen patterns shows that the addition of c33c and c22-3 antigens to RIBA-2 has improved the sensitivity of this test. RIBA-2 also has the advantage of resolving 87.5% of the RIBA-1-indeterminate samples.
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